Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR-T for Relapsed/Refractory ALL and Lymphomas
NCT04196205Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Dec 2019
- Primary completion
- Aug 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of autologous anti-CD19 CAR-T cells in acute lymphoblastic leukemia (ALL), lymphoma, sponsored by First Affiliated Hospital of Nanchang University. Status: unknown.
02
Drugs
autologous anti-CD19 CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoma
Beyond the preview
Go deeper on NCT04196205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04196205.